Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020
30 avr. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the...
Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain
27 avr. 2020 07h30 HE
|
Flexion Therapeutics, Inc.
New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide,...
Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
07 avr. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new employees consisting of 9,265 restricted stock...
Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic
01 avr. 2020 07h00 HE
|
Flexion Therapeutics, Inc.
Company signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and commercialization of...
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results
12 mars 2020 16h01 HE
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $73.0 million for full-year 2019, representing more than 220% growth over 2018Analysis of Phase...
Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
11 mars 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman joins...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 mars 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of an aggregate of 8,500...
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020
04 mars 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2019 financial results after the...
Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference
24 févr. 2020 16h30 HE
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 41st Annual Raymond James Institutional Investors...